Research Article

Effect of Hachimijiogan against Renal Dysfunction and Involvement of Hypoxia-Inducible Factor-1α in the Remnant Kidney Model

Table 2

Physiological data of experimental animals.

GroupBody weight (g)Kidney weight (g/100g BW)Systolic blood pressure (mmHg)Diastolic blood pressure (mmHg)Urine volume (mL/day)
BaselineFinalBaselineFinalBaselineFinalBaselineFinal

Sham297.1 ± 11.0325.5 ± 12.00.311 ± 0.04121.4 ± 14.2113.7 ± 10.856.4 ± 13.562.6 ± 16.25.7 ± 3.16.4 ± 2.8
Control261.7 ± 22.9291.6 ± 26.4*0.331 ± 0.05124.3 ± 5.8127.7 ± 8.269.7 ± 6.759.1 ± 12.220.3 ± 6.6**21.1 ± 6.1**
LD-HJG253.6 ± 17.6275.9 ± 24.3*0.341 ± 0.03132.9 ± 27.1130.0 ± 17.274.2 ± 19.162.8 ± 16.217.6 ± 6.7**14.1 ± 6.3**
HD-HJG257.5 ± 16.6295.6 ± 16.4*0.354 ± 0.04122.8 ± 15.6126.3 ± 8.970.1 ± 17.356.9 ± 6.120.6 ± 8.3**18.0 ± 7.1**
Candesartan264.3 ± 14.6276.1 ± 16.6*0.343 ± 0.03121.4 ± 14.6119.7 ± 16.270.9 ± 15.858.5 ± 13.120.2 ± 13.4**16.5 ± 12.8**

LD-HJG: low-dose hachimijiogan; HD-HJG: high-dose hachimijiogan.
Baseline: before drug administration; Final: after 1 week of drug administration.
Data represent mean ± S.D. ( n = 8–10). , versus sham group.